NPHP6 Variant Detection Assays for Renal and Cerebellar Diagnostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nephronophthisis, an autosomal recessive cystic kidney disease, lacks effective molecular characterization and diagnostic tools, leading to inadequate treatment options, particularly for its association with retinal degeneration and cerebellar vermis aplasia in Joubert syndrome.
Innovation Solution
The development of assays and methods for detecting NPHP6 protein and nucleic acid variants, including the use of yeast two-hybrid assays and nucleic acid hybridization, to identify disease-associated sequences and modulate protein interactions, such as those between NPHP6 and ATF4/CREB2, for diagnostic and therapeutic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If molecular characterization of NPHP6 is performed to enable detection of disease variants, then diagnostic capability is improved, but device complexity and assay development requirements increase
Solution Approach 1:
The patent performs preliminary molecular characterization of NPHP6 by determining its amino acid sequence and identifying disease-associated variants before developing detection assays. This preliminary action enables the design of specific antibodies and assay protocols targeted at known pathogenic variants, improving diagnostic precision while managing complexity through focused rather than broad approaches.
Solution Approach 2:
The patent uses antibodies as intermediary molecules to detect NPHP6 variants. These antibodies serve as mediators that specifically bind to disease-associated NPHP6 variants, translating molecular differences into detectable signals. This intermediary approach enables precise detection without requiring direct complex molecular analysis methods.
2Measurement precision
If assays are developed to detect NPHP6 variants associated with Senior-Loken and Joubert syndromes, then diagnostic accuracy is improved, but time and resources for assay development increase
Solution Approach 1:
The patent performs preliminary identification of disease-associated NPHP6 variants and their amino acid sequences before assay development. This preliminary characterization of pathogenic variants enables the direct design of targeted detection assays, reducing the time required for iterative assay development and validation while improving diagnostic accuracy from the outset.
Solution Approach 2:
The patent uses feedback from molecular characterization data and disease association studies to refine and optimize detection assays. By incorporating information about which specific NPHP6 variants are associated with Senior-Loken and Joubert syndromes, the assay development process is guided and accelerated, reducing overall development time while maintaining high diagnostic accuracy.
3Reliability
If protein interactions between NPHP6 and ATF4/CREB2 are modulated for therapeutic purposes, then treatment effectiveness is improved, but mechanism complexity and therapeutic development difficulty increase
Solution Approach 1:
The patent identifies and targets the protein interaction between NPHP6 and ATF4/CREB2 as a therapeutic mechanism. By using small molecules or other modulators as intermediaries to disrupt or enhance this specific protein-protein interaction, the patent aims to correct the molecular defects underlying NPHP without requiring complex gene therapy or cellular reprogramming approaches.
Solution Approach 2:
The patent extracts and focuses on the specific NPHP6-ATF4/CREB2 interaction as a discrete therapeutic target. By isolating this particular molecular mechanism from the complex network of renal development pathways, the patent enables targeted therapeutic intervention that improves effectiveness while managing complexity through focused mechanistic understanding.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the detection of NPHP6 variants indicative of Senior-Loken and Joubert syndromes, providing a basis for improved diagnostics and potential treatments by altering protein interactions that affect gene expression and renal/cerebellar development.
Implementation Method 1
The development of assays and methods for detecting NPHP6 protein and nucleic acid variants, including the use of yeast two-hybrid assays
Implementation Method 2
assays for detecting NPHP6 polymorphisms and mutations associated with disease states
Data Source
AI summary
The present invention relates to Nephronophthisis, in particular to the NPHP6 protein (nephrocystin-6) and nucleic acids encoding the NPHP6 protein. The present invention also provides assays for the detection of NPHP6, and assays for detecting NPHP6 polymorphisms and mutations associated with disease states.